HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GlaxoSmithKline oral care sales

This article was originally published in The Rose Sheet

Executive Summary

Revenues for oral care products rose 71% to $1.59 bil. in 2001 including the Block Drug business, acquired in January 2001. Excluding Block brands, sales for oral care products, led by Aquafresh, were up 3% to $956 mil. "The profits made by Block Drug before we acquired it were doubled" during the year, GSK CEO Jean-Peirre Garnier reported at a year-end analyst presentation Feb. 14. "We were able to do some clever cost-cutting, to expand their franchises, their great brands like Sensodyne, in countries where they were not particularly strong, and we think that is going also to help drive the sales line and the profit line" for the company's consumer business...
UsernamePublicRestriction

Register

RS010046

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel